JP2000506853A5 - - Google Patents

Download PDF

Info

Publication number
JP2000506853A5
JP2000506853A5 JP1997532050A JP53205097A JP2000506853A5 JP 2000506853 A5 JP2000506853 A5 JP 2000506853A5 JP 1997532050 A JP1997532050 A JP 1997532050A JP 53205097 A JP53205097 A JP 53205097A JP 2000506853 A5 JP2000506853 A5 JP 2000506853A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997532050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000506853A (ja
JP4138006B2 (ja
Filing date
Publication date
Priority claimed from US08/611,307 external-priority patent/US6271196B1/en
Application filed filed Critical
Publication of JP2000506853A publication Critical patent/JP2000506853A/ja
Publication of JP2000506853A5 publication Critical patent/JP2000506853A5/ja
Application granted granted Critical
Publication of JP4138006B2 publication Critical patent/JP4138006B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP53205097A 1996-03-05 1997-03-05 プロサポジン由来のペプチドを使用する神経障害痛の軽減方法 Expired - Fee Related JP4138006B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/611,307 US6271196B1 (en) 1996-03-05 1996-03-05 Methods of alleviating neuropathic pain using prosaposin-derived peptides
US08/611,307 1996-03-05
PCT/US1997/004143 WO1997032895A1 (en) 1996-03-05 1997-03-05 Methods of alleviating neuropathic pain using prosaposin-derived peptides

Publications (3)

Publication Number Publication Date
JP2000506853A JP2000506853A (ja) 2000-06-06
JP2000506853A5 true JP2000506853A5 (enExample) 2004-12-02
JP4138006B2 JP4138006B2 (ja) 2008-08-20

Family

ID=24448513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53205097A Expired - Fee Related JP4138006B2 (ja) 1996-03-05 1997-03-05 プロサポジン由来のペプチドを使用する神経障害痛の軽減方法

Country Status (16)

Country Link
US (2) US6271196B1 (enExample)
EP (1) EP0929569B1 (enExample)
JP (1) JP4138006B2 (enExample)
KR (1) KR100507715B1 (enExample)
AT (1) ATE340187T1 (enExample)
AU (1) AU734566B2 (enExample)
CA (1) CA2248139C (enExample)
CZ (1) CZ297384B6 (enExample)
DE (1) DE69736712T2 (enExample)
IL (1) IL126082A0 (enExample)
NO (1) NO984093L (enExample)
NZ (1) NZ331757A (enExample)
PL (1) PL187917B1 (enExample)
RU (2) RU2266129C2 (enExample)
SK (1) SK122898A3 (enExample)
WO (1) WO1997032895A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) * 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US6849602B1 (en) * 1996-03-05 2005-02-01 The Regents Of The University Of California Compositions for alleviating neuropathic pain with prosaposin receptor agonists
JP2001524944A (ja) * 1997-03-05 2001-12-04 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 神経障害性疼痛の緩和方法
WO1998039357A1 (en) * 1997-03-05 1998-09-11 The Regents Of The University Of California Method of alleviating neuropathic pain
CA2284105A1 (en) * 1997-03-24 1998-10-01 John S. O'brien Synthetic saposin c-derived neurotrophic peptides
CA2304108A1 (en) * 1997-09-09 1999-03-18 The Regents Of The University Of California Inhibition of apoptotis using prosaposin receptor agonists
US6458357B1 (en) * 1997-09-09 2002-10-01 Myelos Corporation Retro-inverso neurotrophic and analgesic peptides
CZ2001655A3 (cs) * 1998-08-28 2001-11-14 Myelos Corporation Cyklický peptid, prostředek, způsob indukce myelinizace, způsob potlačení degenerace neuronů a způsob léčby
US20020028783A1 (en) * 1999-09-09 2002-03-07 O'brien John S. Method of stimulating prosaposin receptor activity
USRE45976E1 (en) * 1999-02-24 2016-04-19 Tact Ip, Llc Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally
WO2000058359A1 (en) * 1999-03-30 2000-10-05 Myelos Corporation Retro-inverso prosaposin-derived peptides and use thereof
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7109168B1 (en) 2000-06-16 2006-09-19 Myelos Corporation Retro-inverso peptides derived from leukemia inhibitory factor
US7135461B1 (en) 2000-06-16 2006-11-14 Myelos Corporation Retro-inverso peptides derived from interleukin-6
AU5496500A (en) * 1999-06-16 2001-01-02 Myelos Corporation Retro-inverso peptides derived from interleukin-3
IL147095A0 (en) * 1999-06-16 2002-08-14 Myelos Corp Retro-inverso peptides derived from leukemia inhibitory factor
CA2376479A1 (en) * 1999-06-16 2000-12-21 David E. Wright Retro-inverso peptides derived from interleukin-6
US20050074747A1 (en) * 2000-09-08 2005-04-07 Wadih Arap Biopanning and rapid analysis of selective interactive ligands (brasil)
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US20040170955A1 (en) * 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20060287240A1 (en) * 2001-03-09 2006-12-21 O'brien John S Method of stimulating prosaposin receptor activity
US20040176290A1 (en) * 2001-07-18 2004-09-09 Renata Pasqualini Anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration
US8507445B2 (en) * 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US20040048243A1 (en) * 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
AU2003259846A1 (en) * 2002-08-16 2004-03-03 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
US7166691B2 (en) * 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
WO2004084930A1 (en) * 2003-03-26 2004-10-07 Develogen Aktiengesellschaft Use of saposin-related proteins for preventing and treating obesity, diabetes and/or metabolic syndrome
EP1613321A2 (en) * 2003-03-28 2006-01-11 Acadia Pharmaceuticals Inc. Muscarinic m1 receptor agonists for pain management
US7834147B2 (en) * 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
CN100366286C (zh) * 2003-04-28 2008-02-06 常州南云科技有限公司 Saposin C-DOPS:一种抗癌新药
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
EP1736481A1 (en) * 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
RU2317829C2 (ru) * 2005-10-05 2008-02-27 Федеральное государственное учреждение науки "Екатеринбургский медицинский научный центр профилактики и охраны здоровья рабочих промпредприятий" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ лечения мононевропатий верхних конечностей
US7964585B2 (en) * 2006-03-14 2011-06-21 Case Western Reserve University Composition and method of treating peripheral neuropathy
RU2345786C2 (ru) * 2007-02-27 2009-02-10 Андрей Евгеньевич Кульчиков Способ лечения непрерывно-прогредиентных дегенеративных и демиелинизирующих заболеваний
KR20180123731A (ko) 2008-01-22 2018-11-19 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
RU2561582C2 (ru) * 2010-11-19 2015-08-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Инъекционная лекарственная форма олигопептидного препарата для лечения рассеянного склероза и способ ее получения
WO2012115185A1 (ja) * 2011-02-23 2012-08-30 北海道公立大学法人札幌医科大学 疼痛を治療、改善、または予防するための組成物
RU2669692C1 (ru) * 2017-08-14 2018-10-15 Павел Андреевич Канаев Способ получения комплекса биологически активных пептидов обладающих нейротропной активностью
BR112020018334A2 (pt) 2018-03-23 2021-02-17 Bexion Pharmaceuticals Inc. composições farmacêuticas de saposina c e métodos de tratamento de câncer
SG11202007887VA (en) 2018-03-29 2020-09-29 Lateral IP Pty Ltd Cyclic peptides and uses thereof
EP4274657A4 (en) * 2021-01-09 2024-12-11 Bexion Pharmaceuticals, Inc. METHODS FOR REDUCING NEUROPATHY AND NEUROPATHIC SYMPTOMS AND TREATING CANCER

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3750197D1 (de) 1986-04-22 1994-08-18 Salk Inst For Biological Studi Antagonisten des Fibroblasten-Wachstumsfaktors.
DD298412A5 (de) * 1989-04-28 1992-02-20 ������@���Kk�� Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele
US5169764A (en) * 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
RU2007417C1 (ru) * 1991-06-21 1994-02-15 Российский государственный медицинский университет Способ получения плацентарного протеина
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5534495A (en) * 1993-05-25 1996-07-09 Advanced Peptides And Biotechnology Sciences Treatment of non-HIV neuropathic pain syndromes
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
CA2176708A1 (en) * 1993-11-15 1995-05-26 Christopher A. Maack Method of treating neurological disorders
WO1998039357A1 (en) * 1997-03-05 1998-09-11 The Regents Of The University Of California Method of alleviating neuropathic pain
CA2284105A1 (en) * 1997-03-24 1998-10-01 John S. O'brien Synthetic saposin c-derived neurotrophic peptides

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000507029A5 (enExample)
JP2001507533A5 (enExample)
JP2000501771A5 (enExample)
JP2000501599A5 (enExample)
JP2000507577A5 (enExample)
JP2000502472A5 (enExample)
JP2000501825A5 (enExample)
JP2000509081A5 (enExample)
JP2000502485A5 (enExample)
JP2000502425A5 (enExample)
JP2000506853A5 (enExample)
JP2000502568A5 (enExample)
JP2001507254A5 (enExample)
JP2000501774A5 (enExample)
JP2001503005A5 (enExample)
JP2000515141A5 (enExample)
JP2000502570A5 (enExample)
JP2000513352A5 (enExample)
JP2000501876A5 (enExample)
JP2002514193A5 (enExample)
JP2000501744A5 (enExample)
JP2000502316A5 (enExample)
JP2001508643A5 (enExample)
JP2000502714A5 (enExample)